Tokai Pharmaceuticals

Qiagen, Tokai Pharmaceuticals partner

Wednesday, March 18, 2015

Qiagen, a Netherlands-based holding company, has partnered with Germany-based Tokai Pharmaceuticals to combine new circulating tumor cells (CTCs) technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai’s novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer (CRPC). The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies demonstrated potential utility to guide therapy choice in CRPC patients.

[Read More]

Tokai Pharmaceuticals raises $23 million in funding

Tuesday, September 20, 2011

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $23 million in a Series D3 financing. The proceeds will be used to support the ongoing clinical development of galeterone (TOK-001), the company’s lead drug candidate, which has completed an initial proof-of-concept phase 1 clinical trial for the treatment of patients with castration resistant prostate cancer (CRPC). The financing round included both current investors, Novartis Venture Fund and Apple Tree Partners.

[Read More]